Company intelligence / Profile preview

OcuLuce

Ownership: Private
Development stage: Other

Overview

OcuLuce is an early-stage biotechnology and medical device company focused on developing innovative light-based therapies for ophthalmic conditions. The company's primary focus is on utilizing specific wavelengths of light to treat retinal diseases such as age-related macular degeneration and diabetic retinopathy, as well as ocular surface disorders like dry eye disease. OcuLuce aims to provide non-invasive, home-based treatment options that can slow disease progression and improve patient outcomes. Their technology leverages photobiomodulation to stimulate cellular repair and reduce inflammation in ocular tissues.

Therapeutic areas: Ophthalmology
Modalities: DevicePhototherapy
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on OcuLuce.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OcuLuce.

Explore the full profile